易感性、感染、反应和器官功能障碍(PIRO)临床分期系统在重症监护与普通病房患者中的前瞻性国际验证
该研究是在葡萄牙五家医院和澳大利亚一家机构开展的前瞻性国际队列研究,为期6个月,纳入符合CDC下呼吸道、泌尿道、腹腔和血流感染标准的连续成人患者,共1638例。院内死亡患者PIRO评分更高(10±3 vs 8±4,p<0.001)。I、II、III、IV期观察死亡率分别为3%、15%、24%、34%,除IV期低于原模型预测区间外,其余均在预测区间内;院内生存率为84%。PIRO分期对I期阳性预测值为97%、II期91%、III期85%、IV期66%;全队列AUROC为0.75,仅菌血症患者为0.70。III期和IV期未在理想时间窗内使用抗生素的患者死亡率高于及时使用者。
要点
- 1638例感染患者中,院内死亡者PIRO评分高于存活者(10±3 vs 8±4,p<0.001)。
- PIRO I、II、III、IV期观察院内死亡率分别为3%、15%、24%、34%,IV期低于原模型预测区间。
- PIRO分期阳性预测值:I期97%、II期91%、III期85%、IV期66%。
- 全队列AUROC为0.75,仅菌血症患者为0.70。
- III期和IV期未在理想时间窗内使用抗生素者死亡率高于及时使用者。
适用人群与场景
- 葡萄牙五家医院和澳大利亚一家机构中,连续入住选定病房或重症监护室的成人患者。
- 感染符合CDC下呼吸道、泌尿道、腹腔和血流感染标准。
诊断标准与关键阈值
- 采用PIRO(易感性、感染、反应和器官功能障碍)临床分期系统进行分期,分为I、II、III、IV期。
红旗征与不能漏的情况
- III期和IV期患者未在理想时间窗内使用抗生素与更高死亡率相关。
研究设计与关键结果
- 研究类型为前瞻性国际队列研究,为期6个月,纳入1638例患者。
- 院内死亡患者PIRO评分10±3,存活者8±4,p<0.001。
- I、II、III、IV期观察死亡率分别为3%、15%、24%、34%,除IV期低于原模型预测区间外,其余在预测区间内。
- 院内生存率84%。
- PIRO分期阳性预测值:I期97%、II期91%、III期85%、IV期66%。
- 全队列AUROC为0.75,仅菌血症患者为0.70。
- III期和IV期未在理想时间窗内使用抗生素者死亡率高于及时使用者。
证据类型、等级与局限
- 证据类型:前瞻性国际队列研究(外部验证)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,未来研究可基于疾病分期将PIRO系统应用于特定治疗干预的决策和临床试验入组。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Stratifying patients with sepsis was the basis of the predisposition, infection, response and organ dysfunction (PIRO) concept, an attempt to resolve the heterogeneity in treatment response. The purpose of this study is to perform an independent validation of the PIRO staging system in an international cohort and explore its utility in the identification of patients in whom time to antibiotic treatment is particularly important.
METHODS: Prospective international cohort study, conducted over a 6-month period in five Portuguese hospitals and one Australian institution. All consecutive adult patients admitted to selected wards or the intensive care, with infections that met the CDC criteria for lower respiratory tract, urinary, intra-abdominal and bloodstream infections were included.
RESULTS: There were 1638 patients included in the study. Patients who died in hospital presented with a higher PIRO score (10 ± 3 vs 8 ± 4, p < 0.001). The observed mortality was 3%, 15%, 24% and 34% in stage I, II, III and IV, respectively, which was within the predicted intervals of the original model, except for stage IV patients that presented a lower mortality. The hospital survival rate was 84%. The application of the PIRO staging system to the validation cohort resulted in a positive predictive value of 97% for stage I, 91% for stage II, 85% for stage III and 66% for stage IV. The area under the receiver operating characteristics curve (AUROC) was 0.75 for the all cohort and 0.70 if only patients with bacteremia were considered. Patients in stage III and IV who did not have antibiotic therapy administered within the desired time frame had higher mortality rate than those who have timely administration of antibiotic.
CONCLUSIONS: To our knowledge, this is the first external validation of this PIRO staging system and it performed well on different patient wards within the hospital and in different types of hospitals. Future studies could apply the PIRO system to decision-making about specific therapeutic interventions and enrollment in clinical trials based on disease stage.
参考来源
- Cardoso T, Rodrigues PP, Nunes C, et al. Prospective international validation of the predisposition, infection, response and organ dysfunction (PIRO) clinical staging system among intensive care and general ward patients. Ann Intensive Care. 2021. PMID: 34950977. doi:10.1186/s13613-021-00966-7
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。